Aquestive Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
FDA requested additional human factors and PK studies for Anaphylm, with resubmission planned for Q3. Market demand for needle-free epinephrine remains strong, and launch preparations are supported by robust cash reserves and expanded medical affairs efforts.
-
Anaphylm remains the central focus, with remediation efforts on track for Q3 2024 resubmission and potential early 2025 approval. The company is well-capitalized, expanding its sales force, and expects strong adoption among younger patients, with broader pipeline and market opportunities ahead.
-
The company is advancing a sublingual epinephrine film, Anaphylm, targeting the growing severe allergy market and aiming to replace auto-injectors with a more convenient alternative. Regulatory resubmission is planned for Q3, with potential approval in Q1 2027, supported by a strong cash position and a ready commercial team.
-
FDA issued a CRL for Anaphylm, requiring new human factors and PK studies but raising no safety or efficacy concerns. The company expects to resubmit by Q3, with commercial and global launch preparations ongoing and strong market interest indicated.
Fiscal Year 2025
-
Anaphylm NDA resubmission is on track for Q3 2026, with expanded clinical and commercial teams and strong financial backing. 2025 saw revenue growth in manufacturing, higher SG&A due to legal and launch prep, and a net loss of $83.8M. 2026 guidance projects up to $50M in revenue and a narrowed EBITDA loss.
-
Anaphylm's commercial launch is prioritized for late Q1 with a targeted sales force and focused allergist strategy. Financial resources are secured through 2027, regulatory progress is positive, and clinical data show rapid symptom resolution and robust efficacy, supporting market expansion potential.
-
Q3 2025 saw revenue growth excluding one-time items, strong cash reserves, and major financing secured to support the Anaphylm launch, pending FDA approval. Pre-launch activities and international regulatory progress are on track, with leadership and pipeline expansion underway.
-
Aquestive presented its Anaphylm sublingual film for anaphylaxis, highlighting rapid action, ease of use, and strong commercial readiness ahead of a potential FDA approval in January. Over $200M in funding supports a U.S. launch, with global expansion and robust patient support planned.
-
FDA will not require an advisory committee for Anaphylm, reflecting a positive review process. The company is well-funded for launch, targeting allergists and pediatricians, and expects early adoption among younger patients and parents. International expansion and pipeline development are underway.
-
Q2 2025 saw steady operational progress, with Anaphylm on track for FDA review and launch preparations, revenue of $10M, and a net loss of $13.5M. Full-year guidance is unchanged, and the company is confident in securing launch financing and broad market access for Anaphylm.
-
Q1 2025 saw a 28% revenue decline and a widened net loss as focus shifted to the Anaphylm launch, with robust pre-commercial activities and capital reallocation. Revised 2025 guidance reflects the removal of Libervant revenue and increased Anaphylm spending.
-
Anaphylm's NDA is under FDA review, with key milestones expected over the next 6–9 months. Pivotal data show strong efficacy and safety, and commercial efforts are focused on awareness and rapid launch readiness. The market for non-injectable epinephrine is poised for significant growth.
-
Anaphylm’s NDA filing is on track, with potential FDA approval in early 2025 and international expansion planned. The product’s unique oral film format addresses unmet needs in severe allergy treatment, while AQST-108 and Libervant offer additional growth opportunities.
-
An NDA filing for a sublingual epinephrine film is imminent, with strong FDA engagement and unique efficacy data supporting commercial launch plans. The company is financially positioned for regulatory milestones and is advancing a topical epinephrine gel for alopecia areata.
Fiscal Year 2024
-
FDA filing for Anaphylm is underway, with a potential Q1 2026 launch. 2024 revenue rose 14% due to one-time items, but core revenue declined; net loss widened. 2025 guidance anticipates lower revenue, higher pre-commercial spending, and continued legal uncertainty for Libervant.
-
Q3 2024 saw new product advances, expanded LiberVent coverage, and strong Anaphil clinical results. Revenue rose 4% year-over-year, but net loss widened due to higher R&D and SG&A. 2024 guidance is unchanged, with key launches and studies on track.
-
The company is advancing its Adrenoverse platform, with Anaphylm expected in 2026, Libervant in 2027, and AQST-108 targeting alopecia areata in 2028. AQST-108 shows strong preclinical results for local immunomodulation without systemic exposure, and the initial clinical focus is on mild to moderate alopecia areata.
-
Aquestive Therapeutics presented at the H.C. Wainwright conference, highlighting its innovative oral drug delivery technologies and pipeline, including Anaphilm, a first-in-class oral epinephrine film targeting a $1–2 billion market. The company projects significant growth, leveraging new product launches and a focused commercial strategy.
-
Q2 2024 saw revenue growth driven by one-time deferred revenue recognition, improved net loss, and strong cash reserves. Anaphylm advanced toward NDA submission, while Libervant expanded in the pediatric market. 2024 guidance was raised, reflecting strategic focus and pipeline progress.